Industry: Treatment for chronic Hepatitis B
Antios is a biopharma company developing unique antiviral therapies for pressing public health issues. One of these is chronic Hepatitis B (HBV), which affects 250 million people around the world. Chronic HBV is one of the top causes of liver cirrhosis and liver cancer.
Antios has identified a promising potential treatment. The company’s lead drug candidate, ATI-2173, could provide a lasting functional cure for patients infected with Hepatitis B. ATI-2173 works by directly targeting the liver and preventing the DNA of the virus from replicating.
Led by a skilled team with impressive experience in developing and commercializing successful antiviral drugs, Antios is well-positioned to tackle this pressing medical need.
Company website: Antios Therapeutics